Author

Yuvika Paliwal

Observed name: Paliwal, Yuvika

Institution: Pfizer (United States)

Observed institution: Pfizer (United States)

OpenAlex ID: A5108937218

Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies

2024 · Amit Chhabra, George Bashirians, et al. · Molecular Therapy — Methods & Clinical Development · 78

Global Seroprevalence of Neutralizing Antibodies Against Adeno-Associated Virus (AAV) Serotypes of Relevance to Gene Therapy

2022 · Professor John Rasko, George Bashirians, et al. · Blood · 4

Preliminary Pharmacodynamic Results from a Multicenter Phase 2/3 Study of Next-Generation HbS Polymerization Inhibitor GBT021601 for the Treatment of Patients with Sickle Cell Disease

2023 · Mira Patel Pochron, Adeseye Michael Akinsete, et al. · Blood · 2

Efficacy and safety of osivelotor in participants with sickle cell disease in a 12-week phase 2, multicenter, open-label, dose-finding trial and extension study

2025 · Santosh Saraf, Shehu Abdullahi, et al. · Journal of sickle cell disease. · 1

An Integrated Framework Predicting Enrollment and Interim Analysis Timing in Clinical Trials with Recurrent Count Outcomes

2026 · Dazheng Zhang, Yuvika Paliwal, et al. · Statistics in Biopharmaceutical Research

An Integrated Framework Predicting Enrollment and Interim Analysis Timing in Clinical Trials with Recurrent Count Outcomes

2026 · Zhang, Dazheng, Paliwal, Yuvika, et al. · Figshare

An Innovative Design Proposal for Investigating Long-Acting Growth Hormone Drug in A Single Master Protocol Across Multiple Indications with Single Hypothesis Test

2026 · Yuvika Paliwal, Richard Zhang, et al. · Statistics in Biopharmaceutical Research

Generalized linear mixed models for analysis of cross-correlated binary data in multi-reader studies of diagnostic imaging

2017 · Yuvika Paliwal · D-Scholarship@Pitt (University of Pittsburgh)

Works count: 8

Citation count: 85

H-index: 2

I10-index: 1